209 related articles for article (PubMed ID: 20683858)
21. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA.
Rozaklis T; Beard H; Hassiotis S; Garcia AR; Tonini M; Luck A; Pan J; Lamsa JC; Hopwood JJ; Hemsley KM
Exp Neurol; 2011 Jul; 230(1):123-30. PubMed ID: 21515264
[TBL] [Abstract][Full Text] [Related]
22. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
[TBL] [Abstract][Full Text] [Related]
23. Brain Targeting in MPS-IIIA.
Sorrentino NC; Fraldi A
Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():630-8. PubMed ID: 27491210
[TBL] [Abstract][Full Text] [Related]
24. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs.
Yogalingam G; Pollard T; Gliddon B; Jolly RD; Hopwood JJ
Genomics; 2002 Feb; 79(2):150-3. PubMed ID: 11829484
[TBL] [Abstract][Full Text] [Related]
25. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease.
Hemsley KM; Luck AJ; Crawley AC; Hassiotis S; Beard H; King B; Rozek T; Rozaklis T; Fuller M; Hopwood JJ
Eur J Neurosci; 2009 Mar; 29(6):1197-214. PubMed ID: 19302155
[TBL] [Abstract][Full Text] [Related]
26. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain.
Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ
Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350
[TBL] [Abstract][Full Text] [Related]
27. Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
Richard M; Arfi A; Seguin J; Gandolphe C; Scherman D
Gene Ther; 2009 Jun; 16(6):746-56. PubMed ID: 19357715
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.
Yogalingam G; Hopwood JJ
Hum Mutat; 2001 Oct; 18(4):264-81. PubMed ID: 11668611
[TBL] [Abstract][Full Text] [Related]
29. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice.
Gliddon BL; Hopwood JJ
Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919
[TBL] [Abstract][Full Text] [Related]
30. Myeloid/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease.
Sergijenko A; Langford-Smith A; Liao AY; Pickford CE; McDermott J; Nowinski G; Langford-Smith KJ; Merry CL; Jones SA; Wraith JE; Wynn RF; Wilkinson FL; Bigger BW
Mol Ther; 2013 Oct; 21(10):1938-49. PubMed ID: 23748415
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement reduces neuropathology in MPS IIIA dogs.
Crawley AC; Marshall N; Beard H; Hassiotis S; Walsh V; King B; Hucker N; Fuller M; Jolly RD; Hopwood JJ; Hemsley KM
Neurobiol Dis; 2011 Aug; 43(2):422-34. PubMed ID: 21550404
[TBL] [Abstract][Full Text] [Related]
32.
Marcó S; Haurigot V; Bosch F
Hum Gene Ther; 2019 Oct; 30(10):1211-1221. PubMed ID: 31482754
[TBL] [Abstract][Full Text] [Related]
33. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome.
Scott HS; Blanch L; Guo XH; Freeman C; Orsborn A; Baker E; Sutherland GR; Morris CP; Hopwood JJ
Nat Genet; 1995 Dec; 11(4):465-7. PubMed ID: 7493035
[TBL] [Abstract][Full Text] [Related]
34. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice.
Mader KM; Beard H; King BM; Hopwood JJ
Genes Brain Behav; 2008 Oct; 7(7):740-53. PubMed ID: 18518922
[TBL] [Abstract][Full Text] [Related]
35. SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors.
Lau AA; Hopwood JJ; Kremer EJ; Hemsley KM
Mol Genet Metab; 2010 Jun; 100(2):168-75. PubMed ID: 20231109
[TBL] [Abstract][Full Text] [Related]
36. Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer.
Ghodsi A; Stein C; Derksen T; Martins I; Anderson RD; Davidson BL
Exp Neurol; 1999 Nov; 160(1):109-16. PubMed ID: 10630195
[TBL] [Abstract][Full Text] [Related]
37. Purification and characterization of recombinant murine sulfamidase.
Gliddon BL; Yogalingam G; Hopwood JJ
Mol Genet Metab; 2004 Nov; 83(3):239-45. PubMed ID: 15542395
[TBL] [Abstract][Full Text] [Related]
38. The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).
Meyer A; Kossow K; Gal A; Steglich C; Mühlhausen C; Ullrich K; Braulke T; Muschol N
Hum Mutat; 2008 May; 29(5):770. PubMed ID: 18407553
[TBL] [Abstract][Full Text] [Related]
39. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
Maccari F; Sorrentino NC; Mantovani V; Galeotti F; Fraldi A; Volpi N
Metab Brain Dis; 2017 Feb; 32(1):203-210. PubMed ID: 27585464
[TBL] [Abstract][Full Text] [Related]
40. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.
Sorrentino NC; D'Orsi L; Sambri I; Nusco E; Monaco C; Spampanato C; Polishchuk E; Saccone P; De Leonibus E; Ballabio A; Fraldi A
EMBO Mol Med; 2013 May; 5(5):675-90. PubMed ID: 23568409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
